

INTRODUCTION	XV
PRESCRIPTION DRUG PRICING POLICY AND DRUG INDUSTRY	
PROFITABILITY	XV
STUDY BACKGROUND	XV
STUDY GOALS AND OBJECTIVES	XVI
INTENDED AUDIENCE	XVI
SCOPE AND FORMAT	XVI
METHODOLOGY AND INFORMATION SOURCES	XVII
ANALYST CREDENTIALS	XVIII
RELATED BCC, INC. RESEARCH	XVIII
BCC ONLINE SERVICES	XIX
EXECUTIVE SUMMARY	XX
SUMMARY TABLE U.S. PRESCRIPTION DRUG MARKET BY PRICE SEGMENT, THROUGH 2008 (\$ BILLIONS)	XXI
OVERVIEW OF U.S. PRESCRIPTION DRUG MARKET	1
MARKET SIZE AND SEGMENTATION	1
FIGURE 1 TRENDS IN U.S. PRESCRIPTION DRUG EXPENDITURES VS. TOTAL HEALTH CARE EXPENDITURES, 2000-2002 (\$ BILLIONS)	1
FIGURE 1 (CONTINUED)	2
THERAPEUTIC CATEGORY	2
Comparison of Therapeutic Drug Sales	3
FIGURE 2 U.S. PRESCRIPTION MARKET SHARES BY THERAPEUTIC CATEGORY, 2002 (PERCENT OF TOTAL SALES)	3
SALES/DISTRIBUTION CHANNELS	4
Sales Channels	4
FIGURE 3 U.S. PRESCRIPTION DRUG SALES CHANNELS, 2002 (% OF TOTAL SALES)	4
FIGURE 3 (CONTINUED)	5
Wholesale Distribution Channels	6
Direct Distribution	6
FIGURE 4 U.S. PRESCRIPTION DRUG MANUFACTURER DIRECT SALES TO DISPENSERS (%)	6
Wholesalers	7
RISING COST OF PRESCRIPTION DRUGS	8
RECENT PRICE TRENDS	8
FIGURE 5 TRENDS IN AVERAGE U.S. RETAIL PRESCRIPTION PRICES, 1990- 2002 (AVERAGE DOLLARS PER PRESCRIPTION)	8
FIGURE 5 (CONTINUED)	9
FORCES DRIVING UP COSTS	9
PRESCRIPTION DRUG BASKET	10
TABLE 1 AVERAGE VALUE OF PRESCRIPTION DRUG BASKET, 2002 (\$)	10
CENTRAL NERVOUS SYSTEM AGENTS	11
TABLE 2 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST SELLING CNS AGENTS IN THE U.S., 2002	11

CARDIOVASCULAR AGENTS	11
TABLE 3 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST SELLING CARDIOVASCULAR AGENTS IN THE U.S., 2002	12
GASTROINTESTINAL AGENTS.....	12
TABLE 4 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING GASTROINTESTINAL AGENTS IN THE U.S., 2002	13
RESPIRATORY AGENTS.....	13
TABLE 5 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING RESPIRATORY AGENTS IN THE U.S., 2002	13
ANTI-INFECTIVE AGENTS.....	14
TABLE 6 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING ANTI-INFECTIVE AGENTS IN THE U.S., 2002.....	14
GENITO-URINARY AGENTS.....	15
TABLE 7 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING GENITO-URINARY AGENTS IN THE U.S., 2002.....	15
MUSCULO-SKELETAL AGENTS.....	15
TABLE 8 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING MUSCULO-SKELETAL AGENTS IN THE U.S., 2002.....	16
ANTI-CANCER AGENTS.....	16
TABLE 9 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING ANTI-CANCER AGENTS IN THE U.S., 2002.....	17
DERMATOLOGICAL AGENTS	17
TABLE 10 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING DERMATOLOGICAL AGENTS IN THE U.S., 2002.....	18
BLOOD AGENTS.....	18
TABLE 11 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING BLOOD AGENTS IN THE U.S., 2002	18
DIABETES DRUGS	19
TABLE 12 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING DIABETES DRUGS IN THE U.S., 2002	19
DIURETICS.....	19
TABLE 13 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST SELLING DIURETICS IN THE U.S., 2002	20
HORMONE SUPPLEMENTS AND CONTRACEPTIVES	20
TABLE 14 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING HORMONE SUPPLEMENTS/CONTRACEPTIVES IN THE U.S., 2002.....	20
OPHTHALMIC AGENTS	21
TABLE 15 SALES, NUMBER OF PRESCRIPTIONS AND AVERAGE VALUE OF BEST-SELLING OPHTHALMIC AGENTS IN THE U.S., 2002.....	21
PUBLIC AND PRIVATE SECTOR RESPONSES TO RISING DRUG COSTS	22
PRIVATE SECTOR RESPONSES TO RISING DRUG COSTS	22
INCREASING USE OF GENERIC DRUGS.....	22
FIGURE 6 TRENDS IN GENERIC DRUG SHARE OF U.S. PRESCRIPTIONS, 1990- 2002 (PERCENT OF TOTAL NUMBER OF PRESCRIPTIONS).....	23
FIGURE 7 AVERAGE COST OF GENERIC VS. BRAND-NAME PRESCRIPTION DRUGS, 2001 (\$).....	24
GROWING POPULARITY OF DISCOUNT SALES CHANNELS	24
Growth Rates	25

<i>FIGURE 8 GROWTH RATES BY PRESCRIPTION DISTRIBUTION CHANNEL, 2001-2002</i>	25
Projected Market Shares	26
<i>FIGURE 9 PROJECTED CHANGES IN PRESCRIPTION DRUG RETAIL MARKET SHARES, 2002-2008 (PERCENT OF TOTAL RETAIL SALES)</i>	26
INTERNATIONAL PURCHASES.....	27
GROUP PURCHASING ORGANIZATIONS	28
Group Purchasing Organizations (Continued).....	29
Rebate Negotiations with Drug Manufacturers.....	30
Development of Pharmacy Networks	30
Formulary Management	31
Drug Utilization Reviews	31
Generic Drug Substitution	31
Disease State Management Programs.....	32
Impact of PBMs on Drug Costs.....	32
PRESCRIPTION DRUG DISCOUNT CARD PROGRAMS	32
Program Features.....	33
Advantages and Disadvantages.....	33
Manufacturers Discount Cards.....	34
<i>TABLE 16 SUMMARY OF MANUFACTURER DRUGS DISCOUNT CARD PROGRAMS</i>	34
<i>TABLE 16 (CONTINUED)</i>	35
Affinity Organization Programs	35
Private Programs.....	36
PUBLIC SECTOR RESPONSES TO RISING DRUG COSTS.....	36
FEDERAL PROGRAMS.....	36
Medicare.....	36
Medigap.....	36
Medicare+Choice.....	37
Pharmacy Plus Waivers	37
Medicaid Drug Rebate Program	38
Other Federal Discount Programs.....	38
Public Health Service (340B) Discount Program	38
Federal Supply Schedule	39
“Big 4” Federal Ceiling Price.....	40
Sub-Ceiling Prices.....	40
STATE PROGRAMS	41
State Drug Discount Card Programs.....	41
Bulk Pharmaceutical Purchasing	42
Supplemental State Rebate Programs	42
Reduced Reimbursements	43
Legal Environment	44
Cost Controls.....	44
MAJOR PRICE SEGMENTS	45
DEFINITIONS	45

PHARMACEUTICAL PRICING TERMS	45
TABLE 17 PHARMACEUTICAL PRICING DEFINITIONS.....	45
TABLE 17 (CONTINUED).....	46
PRICE TO FINAL PURCHASER.....	46
TABLE 18 FINAL DRUG PRICING FOR DIFFERENT TYPES OF CUSTOMERS (\$)	46
Cash Customers.....	47
Private Insurers.....	47
Medicaid.....	48
PRICE SEGMENTS.....	48
FIGURE 10 MAJOR PRICE BREAKS IN THE U.S. PRESCRIPTION DRUG MARKET (AVERAGE COST FOR A REPRESENTATIVE BASKET OF PRESCRIPTION DRUGS).....	48
CASH CUSTOMERS.....	49
TABLE 19 RETAIL CASH CUSTOMER COST OF PRESCRIPTION DRUG BASKET, BY TYPE OF OUTLET (\$).....	50
Savings Mechanisms Impact.....	50
OTHER PRIVATE BUYERS	51
PUBLIC SECTOR BUYERS.....	51
Public Sector Buyers (Continued).....	52
TRENDS IN PRESCRIPTION DRUG PRICE SEGMENTS	53
SALES BY PRICE SEGMENT, 2000-2002.....	53
MARKET SHARES	53
FIGURE 11 PRESCRIPTION DRUG MARKET SHARES BY PRICE SEGMENT, 2002 (PERCENT OF TOTAL SALES).....	54
GROWTH TRENDS, 2000 TO 2002	54
TABLE 20 U.S. PRESCRIPTION DRUG SALES TRENDS BY PRICE SEGMENT, 2000-2002 (\$ BILLIONS, PERCENT OF TOTAL SALES).....	55
Cash Customers.....	55
Insurers and PBMs	55
Hospitals, HMOs and Other Health Care Providers	55
Medicaid.....	56
Federal Supply Schedule.....	56
340B Sales.....	56
Federal Ceiling Price	56
DVA/DOD National Contracts	57
PROJECTED SALES, 2003 THROUGH 2008	57
OVERALL MARKET TRENDS, 2003 THROUGH 2008.....	57
FIGURE 12 OVERALL TRENDS IN THE U.S. PRESCRIPTION DRUG MARKET, 2000-2008 (\$ BILLIONS).....	57
FIGURE 12 (CONTINUED)	58
GROWTH TRENDS BY PRICE SEGMENT, 2003 THROUGH 2008	58
TABLE 21 PRESCRIPTION DRUG SALES TRENDS BY PRICE SEGMENT, THROUGH 2008 (\$ BILLIONS, PERCENT OF TOTAL SALES)	58
Retail Drug Sales.....	59
FIGURE 13 PROJECTED TOTAL RETAIL EXPENDITURES ON PRESCRIPTION DRUGS, 2002-2008* (\$ BILLIONS).....	59

Non-Medicaid Retail Market	59
<i>FIGURE 14 CASH CUSTOMER SHARE OF NON-MEDICAID RETAIL PRESCRIPTION MARKET, 2000-2008 (PERCENT OF TOTAL NON-MEDICAID RETAIL MARKET)</i>	60
Cash Customer Sales Projections for 2003 through 2008.....	61
<i>FIGURE 15 PROJECTED PRESCRIPTION DRUG SALES TO CASH CUSTOMERS, 2002-2008 (\$ BILLIONS)</i>	61
Insurers and PBMs Sales Projections 2003 through 2008.....	62
<i>TABLE 22 PROJECTED PRESCRIPTION SALES TO INSURERS/PBMS, THROUGH 2008 (\$ BILLIONS)</i>	62
Medicaid	62
<i>FIGURE 16 TRENDS IN PRESCRIPTION DRUGS AS A PERCENTAGE OF TOTAL MEDICAID SPENDING, 1998-2002 (% OF TOTAL MEDICAID SPENDING)</i>	62
<i>FIGURE 16 (CONTINUED)</i>	63
<i>FIGURE 17 PROJECTED TRENDS IN MEDICAID SPENDING ON PRESCRIPTION DRUGS, 2002-2008 (\$ BILLIONS)</i>	63
<i>FIGURE 17 (CONTINUED)</i>	64
Hospitals, HMOs, and Other Large Health Care Providers.....	64
<i>FIGURE 18 TRENDS IN PRESCRIPTION DRUG SALES AS A PERCENTAGE OF TOTAL HOSPITAL AND OTHER HEALTH CARE PROVIDER COSTS, 2000-2002</i>	65
Hospital and Other Healthcare Sales Projections 2003 through 2008.....	65
Federal Supply Schedule.....	66
<i>FIGURE 19 PROJECTED TRENDS IN FEDERAL SUPPLY SCHEDULE SPENDING ON PRESCRIPTION DRUGS, 2002-2008 (\$ BILLIONS)</i>	66
340B Prices	67
<i>FIGURE 20 PROJECTED TRENDS IN 340B SPENDING ON PRESCRIPTION DRUGS, 2002-2008 (\$ BILLIONS)</i>	67
Federal Ceiling Prices	68
Department of Defense and Veterans Administration Healthcare Expenditures.....	68
<i>FIGURE 21 PROJECTED INCREASES IN DOD/DVA MEDICAL AND HEALTHCARE SPENDING, 2002-2008 (\$ BILLIONS)</i>	68
<i>FIGURE 21 (CONTINUED)</i>	69
<i>FIGURE 22 TOTAL DOD/DVA PRESCRIPTION DRUG EXPENDITURES, 2000-2008 (\$ BILLIONS)</i>	69
<i>FIGURE 22 (CONTINUED)</i>	70
<i>FIGURE 23 PROJECTED TRENDS IN DVA/DOD PRESCRIPTION DRUG EXPENDITURES UNDER FCP, 2002-2008 (\$ BILLIONS)</i>	70
<i>FIGURE 23 (CONTINUED)</i>	71
National Contracts	71
<i>FIGURE 24 PROJECTED TRENDS IN DVA/DOD PRESCRIPTION DRUG EXPENDITURES UNDER NATIONAL CONTRACTS, 2002-2008 (\$ BILLIONS)</i>	71
<i>FIGURE 24 (CONTINUED)</i>	72
MARKET SHARE BY PRICE SEGMENT, 2003 THROUGH 2008	72
<i>FIGURE 25 PRESCRIPTION DRUG MARKET SHARES BY PRICE SEGMENT, 2003 AND 2008 (PERCENT OF TOTAL SALES)</i>	73

DEVELOPMENTS THAT COULD INFLUENCE BASELINE PROJECTIONS	74
“DISCOUNT-ONLY” PROGRAMS	74
VERMONT PHARMACY DISCOUNT PROGRAM.....	74
“HEALTHY MAINE” PROGRAM.....	75
FUTURE INITIATIVES	75
MEDICARE PRESCRIPTION DRUG BENEFIT.....	75
RECENT ADMINISTRATION PROPOSALS.....	76
Summary of President’s Medicare Plan	76
CONGRESSIONAL PROPOSALS.....	77
IMPACTS	78
THREE LEGISLATIVE SCENARIOS	78
Scenario Impacts on Drug Sales	79
TABLE 23 <i>BASELINE PRESCRIPTION DRUG SALES VS. SCENARIOS 1-3, 2003 AND 2008 (\$ BILLIONS)</i>	79
Scenario Impacts on Market Price Structure.....	79
FIGURE 26 <i>PRICE STRUCTURE OF PRESCRIPTION DRUG MARKET UNDER DIFFERENT SCENARIOS, 2008 (% OF TOTAL SALES)</i>	80
Scenario 1 (Medicare Prescription Drug Benefit)	
Description.....	81
Impact on Drug Sales and Market Structure by Price Segment	82
TABLE 24 <i>POTENTIAL IMPACT OF MEDICARE PRESCRIPTION DRUG BENEFIT ON MARKET SIZE AND STRUCTURE BY SEGMENT, 2003 THROUGH 2008 (\$ BILLIONS)</i>	83
Scenario 2 (State Discount Cards Only) Description	83
Impact on Drug Sales and Market Structure by Price Segment	83
Impact on Drug Sales and Market Structure by Price Segment (Continued).....	84
TABLE 25 <i>POTENTIAL IMPACT OF STATE DISCOUNT-ONLY CARDS ON MARKET SIZE AND STRUCTURE, 2003 THROUGH 2008 (\$ BILLIONS)</i>	85
Scenario 3 (Medicaid Prescription Drug Benefit Plus State Discount-Only Card for Low-Income Uninsured)	
Description.....	85
Impact on Drug Sales and Market Structure by Price Segment	85
TABLE 26 <i>POTENTIAL IMPACT OF MEDICARE DRUG BENEFIT PLUS STATE DISCOUNT-ONLY CARDS ON MARKET SIZE AND STRUCTURE, 2003 THROUGH 2008 (\$ BILLIONS)</i>	86
PRESCRIPTION DRUG INDUSTRY	87
LEADING DRUG MANUFACTURER REVENUES.....	87
TABLE 27 <i>TOP U.S. DRUG COMPANY REVENUES, 2000-2002 (\$ BILLIONS)</i>	87
LEADING DRUG MANUFACTURER PROFITABILITY	88
TABLE 28 <i>TOP U.S. DRUG COMPANY PROFITABILITY, 2000-2002 (NET INCOME AS A PERCENT OF TOTAL REVENUES)</i>	88

TABLE 29 MOST PROFITABLE FORTUNE 500 INDUSTRIES, 2002.....	89
FORTUNE 500 DRUG COMPANY OPERATING PERFORMANCE	89
FIGURE 27 FORTUNE 500 DRUG COMPANIES' APPLICATION OF REVENUES, 2002 (PERCENT OF TOTAL REVENUES).....	89
FIGURE 27 (CONTINUED)	90
PHARMACEUTICAL WHOLESALERS.....	90
FINANCIAL PERFORMANCE	90
TABLE 30 SELECTED DRUG WHOLESALER FINANCIAL PERFORMANCE, 2000- 2002 (\$ BILLIONS/PERCENT)	90
TABLE 30 (CONTINUED).....	91
OPERATING PERFORMANCE	91
FIGURE 28 MAJOR DRUG WHOLESALER APPLICATION OF REVENUES, 2002 (PERCENT OF TOTAL REVENUES).....	91
FIGURE 28 (CONTINUED)	92
PHARMACIES AND OTHER DRUG RETAILERS	92
FINANCIAL PERFORMANCE	92
TABLE 31 SELECTED DRUG RETAILER FINANCIAL PERFORMANCE, 2000-2002 (\$ BILLIONS/PERCENT)	93
OPERATING PERFORMANCE	93
FIGURE 29 SELECTED DRUG RETAILER APPLICATION OF REVENUES, 2002 (PERCENT OF TOTAL REVENUES).....	94
IMPACTS OF PRICE SEGMENTATION	95
IMPACT OF PRICE SEGMENTS ON OVERALL PRESCRIPTION DRUG COSTS.....	95
FIGURE 30 TRENDS IN DISCOUNT SALES VS. AVERAGE PRICE OF PRESCRIPTION DRUGS, 2000-2002 (2000 = 1.0)	96
IMPACT OF PRICE SEGMENTS ON PRICES PAID BY SPECIFIC DRUG CUSTOMER GROUPS.....	97
IMPACT OF PRICE SEGMENTS ON SIZE AND PATTERNS OF DEMAND FOR PRESCRIPTION DRUGS.....	97
IMPACT OF PRICE SEGMENTS ON PRICING TRANSPARENCY AND DECISION-MAKING.....	98
IMPACT OF PRICE SEGMENTS ON DRUG INDUSTRY FINANCIAL PERFORMANCE.....	99
VALUE CHAIN ANALYSIS	100
FIGURE 31 AVERAGE PRESCRIPTION DRUG VALUE CHAIN (\$).....	101
Value Chain Analysis by Price Segment	102
TABLE 32 VALUE CHAIN BY PRICE SEGMENT (\$)	102
Cash Sales	102
Insurers/PBMs	103
Hospitals/HMOs.....	103
Medicaid	103
Federal Programs	104
PROFITABILITY IMPACTS OF POTENTIAL CHANGES IN PRICE STRUCTURE.....	104
Impact on Drug Manufacturers	104

<i>TABLE 33 IMPACT OF SALES PROJECTIONS ON DRUG MANUFACTURERS' PROFITABILITY, THROUGH 2008</i>	105
Drug Retailers	106
CONCLUSIONS	107
Conclusions (Continued)	108
APPENDIX	109
STATE DISCOUNT DRUG PROGRAMS FOR SENIORS	109
<i>TABLE 34 STATE DRUG DISCOUNT PROGRAM CHARACTERISTICS</i>	109
<i>TABLE 34 (CONTINUED)</i>	110
<i>TABLE 34 (CONTINUED)</i>	111
<i>TABLE 34 (CONTINUED)</i>	112
PRESCRIPTION DRUG BASKET PRICES	113
<i>TABLE 35 INDEPENDENT PHARMACY PRESCRIPTION DRUG BASKET PRICES, 2003</i>	113
<i>TABLE 35 (CONTINUED)</i>	114
<i>TABLE 36 CHAIN PHARMACY PRESCRIPTION DRUG BASKET PRICES, 2003</i>	114
<i>TABLE 37 MASS MERCHANTS PRESCRIPTION DRUG BASKET PRICES, 2003</i>	115
<i>TABLE 38 MAIL ORDER PRESCRIPTION DRUG BASKET PRICES, 2003</i>	116
<i>TABLE 39 INTERNET PHARMACY PRESCRIPTION DRUG BASKET PRICES, 2003</i>	117
<i>TABLE 40 OFFSHORE PHARMACY PRESCRIPTION DRUG BASKET PRICES, 2003</i>	118
<i>TABLE 41 INSURERS/PBMS PRESCRIPTION DRUG BASKET PRICES, 2003</i>	119
<i>TABLE 42 HOSPITAL/HMO PRESCRIPTION DRUG BASKET PRICES, 2003</i>	120
<i>TABLE 43 MEDICAID PRESCRIPTION DRUG BASKET PRICES, 2003</i>	121
<i>TABLE 44 FEDERAL SUPPLY SCHEDULE PRESCRIPTION DRUG BASKET PRICES, 2003</i>	122
<i>TABLE 45 340B PRICE PRESCRIPTION DRUG BASKET PRICES, 2003</i>	123
<i>TABLE 46 FEDERAL CEILING PRICE PRESCRIPTION DRUG BASKET PRICES, 2003</i>	124
<i>TABLE 47 VA/DOD NATIONAL CONTRACT PRESCRIPTION DRUG BASKET PRICES, 2003</i>	125
COMPANY FINANCIAL DATA.....	126
FINANCIAL STATEMENT DATA.....	126
<i>TABLE 48 LARGEST U.S. DRUG MANUFACTURERS 2002 FINANCIAL RESULTS</i>	126
<i>TABLE 49 LARGEST U.S. DRUG WHOLESALERS 2002 FINANCIAL RESULTS</i>	127
<i>TABLE 50 SELECTED U.S. DRUG RETAILERS 2002 FINANCIAL RESULTS</i>	127